CoDa Therapeutics announced that its experimental drug Nexagon to treat chronic venous leg ulcers performed well in midstage clinical trials. The therapy aims to heal wounds faster and increase the incidence of wound healing compared with existing treatment options.
CoDa's wound care product performs well in clinical trial
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||